// App-Quantinova.ai

AB0381 : THE UTILITY OF HYDROXYCHLOROQUINE (HCQ) THERAPY FOR TWO YEARS AS A SPARING CORTICOSTEROID AGENCY IN PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS (SLE)

Researchers

Presenter

  • K. Inoue

Principal Investigators

  • K. Misaki

  • N. Dobashi

  • M. Miyazaki

  • Y. Mako

  • T. Yusuke

  • Y. Imaizumi

Medical Centers

  • Kitaharima Medical Center, Center of Rheumatology, Ono, Japan

  • Kitaharima Medical Center, Center of Rheumatology, Ono, Japan

Locations

  • Japan

Companies

  • N/A

Study Components

Therapeutic Area

  • Autoimmune (AI)

Disease

  • Lupus

Biomarkers

  • Lymphocyte count

  • White Blood Cell

Drug/Treatment

  • Hydroxychloroquine

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved